** Shares of drug maker Kala Bio KALA.O fall 34.6% to $7.12, set for record single-day fall
** Company says its CEO Mark Iwicki has resigned, and President Todd Bazemore has been appointed as interim CEO
** Iwicki has been with KALA for nearly a decade
** Iwicki will continue as chair of the board
** KALA is set to report mid-stage trial data of its drug, KPI-012, in the second quarter of 2025, for the treatment of persistent corneal epithelial defects, a condition where injuries to the cornea, the clear front part of the eye, don't heal properly
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.